The role of digitalis in the treatment of heart failure

Related Experiment Videos

C Demers1, R S McKelvie, S Yusuf

  • 1McMaster University, Hamilton Health Sciences Corporation-General Division, Ontario, Canada.

Coronary Artery Disease
|September 4, 1999
PubMed

Insights

Digoxin has been a long-standing treatment for congestive heart failure, improving exercise tolerance and ejection fraction. Recent trials confirm its long-term benefits in reducing morbidity for heart failure patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Digoxin has been a cornerstone therapy for congestive heart failure for two centuries.
  • Clinical evidence supports digoxin's positive impact on key cardiac function markers.

Purpose of the Study:

  • To review the established benefits of digoxin in managing congestive heart failure.
  • To evaluate the current clinical role of digoxin based on recent evidence.

Main Methods:

  • Review of clinical trials and scientific literature.
  • Analysis of data on exercise tolerance, ejection fraction, and neurohormone production.
  • Examination of findings from the Digoxin Investigators Group trial.

Main Results:

  • Digoxin improves exercise tolerance and ejection fraction in heart failure patients.
  • Evidence indicates long-term benefits of digoxin in reducing heart failure morbidity.
  • Neurohormone production is favorably affected by digoxin therapy.

Conclusions:

  • Digoxin remains a valuable therapeutic option for congestive heart failure.
  • Recent data reinforce the long-term efficacy and safety of digoxin.
  • The review supports the continued use of digoxin in heart failure management.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.